Immunoglobulin plus firsekibart for Kawasaki disease in children
Treatments studied
Part of Blood & lymphatic, Heart & circulation, Skin clinical trials.
This trial tests whether adding a new medication (firsekibart) to the standard treatment for Kawasaki disease (immunoglobulin) works better than standard treatment alone. It aims to reduce the risk of heart problems and improve recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must have been diagnosed with Kawasaki disease by a doctor.
- The diagnosis must be made within 10 days of the fever starting.
- Your child has not yet received IVIG treatment.
- Your child must be over 28 days old and younger than 18 years.
- Your child has not taken steroids or other immune-suppressing medications in the last month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two treatments—anakinra and IVIG—for children with Kawasaki disease who still have fever after their first standard IVIG treatment. It aims to find which option works better and is safer for “IVIG non-responders” who may be at risk for heart complications.
This study tests whether anakinra, a medicine that calms inflammation, is just as good as the standard treatment for Kawasaki disease in children. The goal is to reduce fever and prevent heart problems.
This trial is testing a way to match children with Kawasaki disease to the best treatment. It looks at specific symptoms and fever duration to see if a child qualifies for the study, which may help doctors give the right treatment faster.
This trial tests whether a cholesterol-lowering medication called atorvastatin can help children whose hearts were damaged by Kawasaki disease (a serious childhood illness that inflames blood vessels). The study may help reduce long-term heart complications.
This study looks at children with Kawasaki disease, a condition that causes inflammation in blood vessels. The goal is to learn more about how it affects kids in Europe and North India.
This study uses artificial intelligence to look at chest X-rays to help doctors find Kawasaki disease earlier. It may lead to faster treatment and better outcomes for children.
Hear when a new Kawasaki Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.